Yilong Zhang

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel V.T. Catenacci, Niall C. Tebbutt, André M. Murad et al. · The Lancet Oncology · 2017 · 338 citations · Full text

Advanced Met-positive Gastric, First-line Therapy, Gastrointestinal Oncology +7

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

Larry K. Kvols, Kjell E. Öberg, Thomas M. O’Dorisio et al. · Endocrine Related Cancer · 2012 · 194 citations · Full text

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

David Cunningham, Niall C. Tebbutt, André M. Murad et al. · Journal of Clinical Oncology · 2015 · 143 citations

First-line Therapy, Esophageal Cancer, Immunology +17

Dynamic dispersion and high-rise release of coal dust in the working surface of a large-scale mine and application of a new wet dust reduction technology

Wen Nie, Bo Yang, Tao Du et al. · Journal of Cleaner Production · 2022 · 136 citations

Engineering, Dust Control, Environmental Engineering +8

A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

Zezhong Liu, Jie Zhou, Wei Xu et al. · Cell Research · 2022 · 99 citations · Full text